HRP20212000T1 - Aminotriazolopiridini kao inhibitori kinaze - Google Patents

Aminotriazolopiridini kao inhibitori kinaze Download PDF

Info

Publication number
HRP20212000T1
HRP20212000T1 HRP20212000TT HRP20212000T HRP20212000T1 HR P20212000 T1 HRP20212000 T1 HR P20212000T1 HR P20212000T T HRP20212000T T HR P20212000TT HR P20212000 T HRP20212000 T HR P20212000T HR P20212000 T1 HRP20212000 T1 HR P20212000T1
Authority
HR
Croatia
Prior art keywords
pyridin
triazolo
amino
methyl
carboxamide
Prior art date
Application number
HRP20212000TT
Other languages
English (en)
Croatian (hr)
Inventor
Junqing Guo
Amy C. HART
John E. Macor
Michael E. Mertzman
William J. Pitts
Steven H. Spergel
Scott Hunter Watterson
Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH
Jie Chen
Carolyn Diane Dzierba
Guanglin Luo
Jianliang Shi
Sing-Yuen Sit
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20212000T1 publication Critical patent/HRP20212000T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HRP20212000TT 2017-02-13 2018-02-12 Aminotriazolopiridini kao inhibitori kinaze HRP20212000T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762458144P 2017-02-13 2017-02-13
EP18707498.4A EP3580220B1 (en) 2017-02-13 2018-02-12 Aminotriazolopyridines as kinase inhibitors
PCT/US2018/017755 WO2018148626A1 (en) 2017-02-13 2018-02-12 Aminotriazolopyridines as kinase inhibitors

Publications (1)

Publication Number Publication Date
HRP20212000T1 true HRP20212000T1 (hr) 2022-04-01

Family

ID=61283335

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20212000TT HRP20212000T1 (hr) 2017-02-13 2018-02-12 Aminotriazolopiridini kao inhibitori kinaze

Country Status (25)

Country Link
US (3) US10913738B2 (enExample)
EP (1) EP3580220B1 (enExample)
JP (1) JP7097373B2 (enExample)
KR (1) KR102549952B1 (enExample)
CN (1) CN110520423B (enExample)
AU (1) AU2018217488B2 (enExample)
BR (1) BR112019016635A2 (enExample)
CA (1) CA3053484A1 (enExample)
CY (1) CY1124978T1 (enExample)
DK (1) DK3580220T3 (enExample)
EA (1) EA039808B1 (enExample)
ES (1) ES2902676T3 (enExample)
HR (1) HRP20212000T1 (enExample)
HU (1) HUE057801T2 (enExample)
IL (1) IL268614B (enExample)
LT (1) LT3580220T (enExample)
MA (1) MA47460A (enExample)
MX (1) MX378515B (enExample)
PL (1) PL3580220T3 (enExample)
PT (1) PT3580220T (enExample)
RS (1) RS62801B1 (enExample)
SG (1) SG11201907335UA (enExample)
SI (1) SI3580220T1 (enExample)
SM (1) SMT202200001T1 (enExample)
WO (1) WO2018148626A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3580220B1 (en) * 2017-02-13 2021-11-17 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
KR102662197B1 (ko) * 2017-10-30 2024-04-29 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서의 아미노이미다조피리다진
JP7307734B2 (ja) 2018-01-26 2023-07-12 ブリストル-マイヤーズ スクイブ カンパニー キナーゼ阻害剤としてのアミノピロロトリアジン
AU2019301628C1 (en) 2018-07-09 2025-02-06 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting NaV1.8
WO2020014243A1 (en) * 2018-07-09 2020-01-16 Lieber Institute, Inc. PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8
CA3112519A1 (en) 2018-09-13 2020-03-19 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
AU2019337612A1 (en) 2018-09-13 2021-05-13 Bristol-Myers Squibb Company 1H-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (RIPK1)
CN113166116B (zh) * 2019-01-25 2022-12-27 北京赛特明强医药科技有限公司 酰胺基桥连杂环类化合物、及其组合物与应用
US20220177462A1 (en) * 2019-03-22 2022-06-09 Genfleet Therapeutics (Shanghai) Inc. Substituted heterocyclic amide compound and preparation method therefor and pharmaceutical use thereof
JP7600228B2 (ja) 2019-10-03 2024-12-16 ブリストル-マイヤーズ スクイブ カンパニー キナーゼ阻害剤としてのインダゾールカルボキサミド
JP7441477B2 (ja) * 2020-02-13 2024-03-01 ▲勁▼方医▲薬▼科技(上海)有限公司 ジヒドロナフチリドン系化合物、その調製方法及び医薬への使用
CN114230565B (zh) * 2020-09-09 2023-10-27 成都奥睿药业有限公司 5-取代吲哚3-酰胺衍生物及其制备方法和用途
CN114262322B (zh) * 2020-09-16 2026-01-06 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
TWI824626B (zh) * 2021-08-02 2023-12-01 大陸商勁方醫藥科技(上海)有限公司 Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型
IL308349A (en) 2021-08-10 2024-01-01 Abbvie Inc NICOTINAMIDE RIPK1 INHIBITORS
TW202345852A (zh) 2022-03-16 2023-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠雜環類化合物、其製備方法及其在醫藥上的應用
CN114989079B (zh) * 2022-06-21 2023-06-23 中国药科大学 Ripk1激酶靶点抑制剂及其医药用途
AR131541A1 (es) 2023-01-07 2025-04-09 Syngenta Crop Protection Ag Compuestos de carboxamida novedosos
WO2025072395A1 (en) * 2023-09-27 2025-04-03 Bristol-Myers Squibb Company Triazolopyridinyl compounds as kinase inhibitors
WO2025109114A1 (en) 2023-11-24 2025-05-30 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025149637A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025149629A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2026008750A1 (en) 2024-07-05 2026-01-08 Syngenta Crop Protection Ag Novel carboxamide compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050288502A1 (en) * 2004-06-25 2005-12-29 Andersen Denise L Substituted heterocyclic compounds and methods of use
MX2008012482A (es) * 2006-03-31 2008-10-10 Abbott Lab Compuestos de indazol.
ES2320955B1 (es) * 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
WO2009068482A1 (en) 2007-11-27 2009-06-04 Cellzome Limited Amino triazoles as pi3k inhibitors
WO2010007100A1 (en) * 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
WO2010057877A1 (en) 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
US8598163B2 (en) 2009-02-04 2013-12-03 Vitae Pharmaceuticals, Inc. Derivatives of [1,3]Oxazin-2-one useful for the treatment of metabolic diseases such as lipid disorders
US9783573B2 (en) 2012-09-18 2017-10-10 Bristol-Myers Squibb Company IAP antagonists
TN2015000542A1 (en) 2013-06-10 2017-04-06 Bayer Pharma AG Novel compounds for the treatment of cancer
CA2958645A1 (en) * 2014-08-21 2016-02-25 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors as medicaments
CN108349970B (zh) * 2015-11-05 2021-03-05 住友化学株式会社 稠合杂环化合物
WO2018017435A1 (en) 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
JP7190906B2 (ja) 2017-01-24 2022-12-16 住友化学株式会社 縮合複素環化合物及びそれを含有する組成物
EP3580220B1 (en) * 2017-02-13 2021-11-17 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
KR102662197B1 (ko) 2017-10-30 2024-04-29 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서의 아미노이미다조피리다진
JP7307734B2 (ja) 2018-01-26 2023-07-12 ブリストル-マイヤーズ スクイブ カンパニー キナーゼ阻害剤としてのアミノピロロトリアジン
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas

Also Published As

Publication number Publication date
SMT202200001T1 (it) 2022-03-21
PL3580220T3 (pl) 2022-02-07
US10913738B2 (en) 2021-02-09
EA201991915A1 (ru) 2019-12-30
US12157733B2 (en) 2024-12-03
KR102549952B1 (ko) 2023-06-29
US20190389859A1 (en) 2019-12-26
SI3580220T1 (sl) 2022-01-31
CN110520423B (zh) 2022-08-23
IL268614B (en) 2021-12-01
AU2018217488A1 (en) 2019-10-03
EA039808B1 (ru) 2022-03-16
MX2019009555A (es) 2019-10-02
EP3580220B1 (en) 2021-11-17
WO2018148626A1 (en) 2018-08-16
ES2902676T3 (es) 2022-03-29
CA3053484A1 (en) 2018-08-16
US20220315580A1 (en) 2022-10-06
SG11201907335UA (en) 2019-09-27
HUE057801T2 (hu) 2022-06-28
BR112019016635A2 (pt) 2020-04-07
AU2018217488B2 (en) 2021-09-23
MA47460A (fr) 2019-12-18
DK3580220T3 (da) 2022-01-10
KR20190117006A (ko) 2019-10-15
IL268614A (en) 2019-10-31
EP3580220A1 (en) 2019-12-18
JP2020507582A (ja) 2020-03-12
US20250074909A1 (en) 2025-03-06
PT3580220T (pt) 2022-01-03
CY1124978T1 (el) 2023-01-05
RS62801B1 (sr) 2022-02-28
JP7097373B2 (ja) 2022-07-07
LT3580220T (lt) 2021-12-27
MX378515B (es) 2025-03-11
CN110520423A (zh) 2019-11-29

Similar Documents

Publication Publication Date Title
HRP20212000T1 (hr) Aminotriazolopiridini kao inhibitori kinaze
RU2454405C2 (ru) Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина
JPWO2019164846A5 (enExample)
JP2021501179A5 (enExample)
HRP20220297T1 (hr) Aminoimidazopiridazini kao inhibitori kinaze
JP2019512482A5 (enExample)
JP2015503571A5 (enExample)
RU2018112237A (ru) Новые бициклические соединения в качестве дуальных ингибиторов atx/ca
RU2013130925A (ru) Оксимовые соединения в качестве средств для повышения уровня холестерина высокой плотности
RU2002134487A (ru) Бензофены как ингибиторы il-1бета и tnf-альфа
JP2016523911A5 (enExample)
FI3883936T3 (fi) Uusia heterosyklisiä yhdisteitä
RU2016102137A (ru) Первичные карбоксамиды в качестве ингибиторов bik
HRP20191821T1 (hr) Antiproliferativni spojevi i načini njihove uporabe
JP2012501312A5 (enExample)
JP2019537571A5 (enExample)
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
JP2016523977A5 (enExample)
JP2017525757A5 (enExample)
RU2011107437A (ru) Ингибиторы кинуренин-3-моноксигеназы
RU2015150946A (ru) Новые соединения для селективных ингибиторов гистондеацетилазы и фармацевтическая композиция, включающая такие соединения
JP2017523215A5 (enExample)
HRP20161011T1 (hr) Aril dihidropiridinoni i piperidinoni kao inhibitori mgat2
RU2019132212A (ru) Селективные ингибиторы hdac6
RU2015144385A (ru) Ациклические цианоэтилпиразолопиридоны в качестве ингибиторов янус-киназы